EMPAVELI shows sustained kidney disease benefits in study

Apellis Pharmaceuticals (APLS) and Sobi presented Phase 3 VALIANT study results at the European Renal Association Congress, showing EMPAVELI significantly reduced proteinuria (68% at week 26, sustained at one year) and stabilized kidney function in C3G and primary IC-MPGN patients, who are at high risk of kidney failure. The FDA and EMA are reviewing marketing applications for EMPAVELI, with an FDA decision expected this summer; however, Apellis recently reported a Q1 2025 earnings miss with EPS of -$0.74 versus an expected -$0.34, leading to mixed analyst outlooks and price target adjustments despite a 12.82% return over the past week.

Analysis

Apellis Pharmaceuticals (APLS) presented compelling Phase 3 VALIANT study data for EMPAVELI® (pegcetacoplan) in treating rare kidney diseases C3G and primary IC-MPGN, demonstrating a significant 68% reduction in proteinuria sustained at one year and stable kidney function, with a consistent safety profile. This positive clinical development, highlighted at the European Renal Association Congress, positions EMPAVELI for a potential FDA approval, with a decision anticipated this summer, which could address a significant unmet need for patients. Despite this promising pipeline news and strong trailing twelve-month revenue growth of 48%, Apellis recently reported a Q1 2025 earnings miss, with an EPS of -$0.74 against a -$0.34 forecast and revenue of $166.8 million versus an expected $197.77 million. This financial underperformance has led to mixed analyst actions: Wells Fargo raised its price target to $29 (Equal Weight), Citi lowered its target to $41 (Buy), and Raymond James downgraded to Outperform with a $52 target. The company maintains a healthy financial footing with a current ratio of 4.08 and a strong market presence with Cyfovri holding a 60% market share in geographic atrophy. The stock has seen a 12.82% return over the past week, and analyst price targets for APLS show a wide range from $18 to $60, reflecting both the high potential upside from EMPAVELI's new indications and the risks highlighted by recent financial results and subsequent analyst revisions.

Key Decisions for Investors

• Investors should closely monitor the FDA's decision on EMPAVELI for C3G/IC-MPGN, expected this summer, as a significant near-term catalyst given the robust Phase 3 VALIANT study results indicating a 68% reduction in proteinuria.
• Carefully weigh the promising EMPAVELI pipeline and strong 48% LTM revenue growth against the recent Q1 2025 earnings and revenue miss, which has prompted varied analyst price target adjustments and rating changes, before making investment decisions.
• Consider Apellis's solid current ratio of 4.08, Cyfovri's 60% market share, and plans for new pivotal studies in H2 2025 as potential long-term growth drivers, while acknowledging the stock's recent run-up and the wide dispersion in analyst price targets which signals considerable uncertainty.